Special Issue

MiRNA Targets in Cancer: Diagnosis, Prognosis and Treatment

Message from the Guest Editor

Over the last decade, miRNAs have become one of the most promising biomarkers in cancer. Numerous studies have shown that these short RNA sequences play a crucial role in the neoplastic process, including cell death regulation, proliferation, signalling, and the formation of metastasis. On the basis of changes in the level of miRNA expression, the detection and differentiation of many pathological conditions, including the development of cancer, are possible. Moreover, miRNAs have been indicated as markers of metastasis, treatment outcome predictors (chemosensitivity, radiosensitivity), and prognostic factors in nearly all types of cancers. However, what is the best strategy to search for miRNAs with the highest predictive value? How many promising results have been validated so far and have the previous results been confirmed? How far are we from using individual miRNAs or complete miRNA profiles in routine clinical practice? With your help, we aim to answer these and many other questions in this Special Issue, entitled MiRNA Targets in Cancer: Diagnosis, Prognosis and Treatment. Research articles and comprehensive reviews are welcome in this Special Issue.

Guest Editor

Prof. Dr. Radosław Mlak

Body Composition Research Laboratory in the Department of Human Physiology, Medical University of Lublin, Radziwiłłowska 11, 20-080 Lublin, Poland

Deadline for manuscript submissions

closed (10 February 2023)

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 7.2
Indexed in PubMed

mdpi.com/si/106424

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/jpm

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 7.2
Indexed in PubMed

mdpi.com/journal/jpm

MDPI

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical
subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).